AUSTRALIA
info@sudapharma.com
Facebook
Twitter
Linkedin
YouTube
+61 8 6142 5555
Menu
About Us
Snapshot
Our People
Leadership Team
Management Team
Corporate Governance and Charters
Technology
Products
Zolpimist™ – Treatment for Insomnia
R&D
i
NKT cell therapy Licence from Imperial College London
Anagrelide: Treatment for Cancer
Sumatriptan: Treatment for Migraine
Cannabinoids (CBD)
Publications
i
NKT Publications
Investors
ASX Announcements
Presentations
Analyst Reports
Media
Contact Us
Annual Reports
30 June 2018
30 June 2017
30 June 2016
Recent Agreements
Latest SUDA Investor Presentation>>
ASX Announcements
22 Oct 21
SUDA becomes Arovella Therapeutics
22 Oct 21
Chile Ministry of Health Approval Granted for ZolpiMist
14 Oct 21
Results of General Meeting
14 Oct 21
GM presentation
30 Sep 21
Appendix 4G and Corporate Governance Statement 2021
